Unraveling the Hallervorden-Spatz syndrome: Pantothenate kinase-associated neurodegeneration is the name . . .

Current Opinion in Pediatrics

Volumn 15, Issue 6, 2003, Pages 572-577

  Hayflick, Susan J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Hallervorden Spatz syndrome; NBIA; Neurodegeneration with brain iron accumulation; Pantothenate kinase; PKAN

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BACLOFEN; CHELATING AGENT; COENZYME A; DOCOSAHEXAENOIC ACID; DOPA; ESSENTIAL FATTY ACID; FATTY ACID; IDEBENONE; IRON; PANTOTHENATE KINASE; PANTOTHENIC ACID; PANTOTHENIC ACID 4' PHOSPHATE; TRIHEXYPHENIDYL; UBIQUINONE;

ACANTHOCYTOSIS; BASAL GANGLION; BRAIN MITOCHONDRION; CHELATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DYSTONIA; ENZYME DEFICIENCY; ENZYME SYNTHESIS; GENETIC DISORDER; GENETICS; GLOBUS PALLIDUS; HALLERVORDEN SPATZ DISEASE; HUMAN; HYPOBETALIPOPROTEINEMIA; NERVE DEGENERATION; NEUROAXONAL DYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RADIOGRAPHY; RETINOPATHY; REVIEW; SPASTICITY;

BRAIN; HALLERVORDEN-SPATZ SYNDROME; HUMANS; IRON; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 0344393012     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200312000-00005     Document Type: Review

References (22)

1. Shevell MI, Peiffer J: Julius Hallervorden's wartime activities: implications for science under dictatorship. Pediatr Neurol 2001, 25:162-165.
2. Shevell M: Hallervorden and history. N Engl J Med 2003, 348:3-4.
3. Zhou B, Westaway SK, Levinson B, et al.: A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001, 28:345-349.
4. Hayflick SJ: Pantothenate kinase-associated neurodegeneration. In Genetics of Movement Disorders, Stefan Pulst, Ed. Academic Press, San Diego, CA, 2002. Description of the diagnosis, nosology and management of PKAN and related disorders.
5. Taylor TD, Litt M, Kramer P, et al.: Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996, 14:479-481. [published erratum appears in Nat Genet 1997, 16:109.]
6. Hayflick SJ, Westaway SK, Levinson B, et al.: Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003, 348:33-40. A detailed description of the clinical and molecular features of PKAN and non-PKAN NBIA.
7. Ching KH, Westaway SK, Gitschier J, et al.: HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002, 58:1673-1674.
8. Hayflick SJ, Penzien JM, Michl W, et al.: Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001, 25:166-169.
9. Higgins JJ, Patterson MC, Papadopoulos NM, et al.: Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology 1992, 42:194-198.
10. Coryell J, Hayflick SJ: (Updated 3/8/03). Pantothenate kinase-associated neurodegeneration. In GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2003. Available at http://www.genetests.org. Accessed 7/28/03. Expert-authored, peer-reviewed, regularly updated review of diagnosis, management, and genetic counseling of patients and families with PKAN and non-PKAN NBIA.
11. Hortnagel K, Prokisch H, Meitinger T: An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet 2003, 12:321-327.
12. Hill JM, Switzer RC III: The regional distribution and cellular localization of iron in the rat brain. Neuroscience 1984, 11:595-603.
13. Perry TL, Norman MG, Yong VW, et al.: Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985, 18:482-489.
14. Yoon SJ, Koh YH, Floyd RA, et al.: Copper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron. Mutat Res 2000, 448:97-104.
15. Park BE, Netsky MG, Betsill WL Jr: Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology 1975, 25:1172-1178.
16. Tripathi RC, Tripathi BJ, Bauserman SC, et al.: Clinicopathologic correlation and pathogenesis of ocular and central nervous system manifestations in Hallervorden-Spatz syndrome. Acta Neuropathol 1992, 83:113-119.
17. Searle AJ, Willson RL: Stimulation of microsomal lipid peroxidation by iron and cysteine. Characterization and the role of free radicals. Biochem J 1983, 212:549-554.
18. Yang EY, Campbell A, Bondy SC: Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Redox Rep 2000, 5:371-375.
19. Jackowski S: Cell cycle regulation of membrane phospholipid metabolism. J Biol Chem 1996, 271:20219-20222.
20. Miyajima H, Adachi J, Tatsuno Y, et al.: Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998, 50:130-136.
21. Afshar K, Gonczy P, DiNardo S, et al.: fumble Encodes a pantothenate kinase homolog required for proper mitosis and meiosis in Drosophila melanogaster. Genetics 2001, 157:1267-1276.
22. Genova ML, Pich MM, Biondi A, et al.: Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp Biol Med 2003, 228:506-513.